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Objective: The aim of this study was to evaluate the clinical outcome of hepatectomy combined with
inferior vena cava (IVC) resection and reconstruction for treatment of invasive liver tumours.
Methods: From February 1995 to September 2010, 2146 patients underwent liver resections in our
hospital's hepatopancreatobiliary unit. Of these, 35 (1.6%) patients underwent hepatectomy with IVC
resection. These patients were included in this study. Data were analysed from a prospectively collected
database.
Results: Resections were carried out for colorectal liver metastasis (CRLM) (n = 21), hepatocellular
carcinoma (n = 6), cholangiocarcinoma (n = 3) and other conditions (n = 5). Resections were carried out
with total vascular occlusion in 34 patients and without in one patient. In situ hypothermic perfusion was
performed in 13 patients; the ante situm technique was used in three patients, and ex vivo resection was
used in six patients. There were four early deaths from multiple organ failure. Postoperative complications
occurred in 14 patients, three of whom required re-operation. Median overall survival was 29 months and
cumulative 5-year survival was 37.7%. Rates of 1-, 2- and 5-year survival were 75.9%, 58.7% and 19.6%,
respectively, in CRLM patients.
Conclusions: Aggressive surgical management of liver tumours with IVC involvement offers the only
hope for cure in selected patients. Resection by specialist teams affords acceptable perioperative
morbidity and mortality rates.
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Introduction
Liver tumours, including hepatocellular carcinoma (HCC), cho-
langiocarcinoma (CC) and metastatic carcinoma, sometimes
directly invade the retrohepatic portion of the inferior vena cava
(IVC) because of the anatomic proximity of this vessel. Liver
resection remains the only potentially curative treatment for
primary and metastatic tumours of the liver. Five-year survival
rates are reported to range from 30% to 50% after liver resection
for primary hepatic malignancies, metastatic colorectal cancer,
and other non-colorectal cancers metastatic to the liver.1–5 Nowa-
days, chemotherapy is not considered to be a curative option and,
if left untreated, these patients often have a median survival of
considerably < 12 months.6 Technical innovations such as portal
vein embolization, two-stage hepatectomies, re-do hepatectomies
and neoadjuvant chemotherapy have all been used to expand the
population of patients who may be considered for hepatic resec-
tion, and favourable clinical outcomes have been reported.7–9
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In the past, patients with hepatic malignancy involving
the IVC were considered poor candidates for surgical manage-
ment and included few 5-year survivors. Suspected involve-
ment of the hepatocaval confluence (HVC) or IVC was long
considered a contraindication for liver resection as a result of
the risks for intraoperative air embolism or torrential haemor-
rhage. The development of innovative surgical techniques and
increasing acceptance of vascular exclusion procedures are
pushing this boundary of hepatic surgery.10–13 Liver resection in
patients with IVC involvement is becoming more common with
the adoption of these techniques and, when necessary, with the
replacement of the IVC using various materials.5,14–17 Most of the
data available consist of case reports or small series that empha-
size the technical aspects of the procedures.18–31 The longterm
outcomes and oncological integrity of such procedures remain
unclear.
To our knowledge, this report represents the largest patient
series focusing on patient-related outcomes after hepatic resection
for malignancy with reconstruction of the IVC to be published.
Materials and methods
All patients who underwent hepatic resection in our hospital’s
hepatopancreatobiliary unit between February 1995 and Sep-
tember 2010 were included in the study. Data from a prospec-
tively collected database were analysed. Preoperative workup
included measurement of serum biochemistry and carcinoem-
bryogenic antigen (CEA) levels, as well as assessment for major
and often prolonged high-risk surgery, which currently involves
cardiopulmorary exercise testing (CPX). Cross-sectional imaging
included staging computed tomography (CT) scans of the chest
and abdomen, as well as an iron oxide magnetic resonance
imaging (MRI) scan to evaluate hepatic anatomy (Fig. 1).
Imaging for all patients considered for surgery was reviewed
at the multidisciplinary team meeting and patients who were
considered resectable on preoperative imaging were offered
surgery.
Intraoperative ultrasound was used routinely to identify occult
tumours. Parenchymal transection was performed using the Cavi-
Pulse Ultrasonic Surgical Aspirator (CUSA; Valleylab, Inc.,
Boulder, CO, USA). Our group has previously reported results
with ex vivo, ante situm and in situ hypothermic perfusion tech-
niques.32 When necessary, hepatic pedicle clamping was employed
using 15-min cycles with 5-min reperfusion intervals. It is our
opinion that anatomical resections are not necessarily indicated if
a macroscopic negative surgical margin can be obtained.33,34 The
location and number of metastases, and any suspicion of vascular
infiltration, were determined with intraoperative ultrasonography
at the time of surgery. Experience with liver transplantation has
Figure 1 Magnetic resonance imaging of a large tumour with inferior
vena cava invasion (white arrows)
Figure 2 Bovine pericardium patch used to reconstruct the inferior
vena cava
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allowed the centre to offer resection for advanced hepatobiliary
tumours that require total vascular exclusion for tumour excision.
The in situ hypothermic liver preservation technique was used
when indicated.35
Selection of procedure
The type of procedure varies according to the location of the
tumour and the extent of caval involvement, which is finally
evaluated during surgery. When involvement of the IVC is
minimal (60 ° circumferentially and 2 cm longitudinally),
control may be established simply by applying a side-biting clamp
to the retrohepatic IVC, allowing direct repair, although a patch of
bovine pericardium is used to avoid narrowing (Fig. 2). Greater
involvement of the IVC mandates resection and replacement with
a synthetic graft. In the early part of our experience, we used
deleted Dacron® tube grafts (Hemashield®; Meadox Medical, Inc.,
Oakland, NJ, USA), but latterly we switched to ring-enforced
polytetrafluoroethylene (PTFE) tube grafts (Gore-Tex®; W. L.
Gore & Associates Inc., Flagstaff, AZ, USA) because they are resis-
tant to compression by abdominal viscera and the regenerating
liver (Fig. 3). The initial experience indicated better survival when
tumours were peeled off the IVC and thus this remains our policy
if the oncological integrity of the procedure is not compromised.32
Exclusion of the liver with preservation of IVC flow
This technique is useful for small-volume contact in the mid areas
of the liver without involvement of the IVC at either the inflow or
outflow of the liver. The portal inflow and hepatic veins are dis-
sected and clamped when they are required extrahepatically. The
hanging manoeuvre has proved to be useful.36
Standard total vascular exclusion
The technical details of total vascular exclusion (TVE) have pre-
viously been published.32 This method involves mobilizing the
liver where possible and isolating the suprahepatic and infrahe-
patic vena cava, as well as the inflow to the liver. The infrahepatic
vena cava, hilum and suprahepatic vena cava are serially clamped.
A venovenous bypass is used in patients who display haemody-
namic intolerance to TVE, despite adequate fluid loading, but this
is rarely needed except in elderly subjects.
The ante situm, in situ hypothermic perfusion and
ex vivo techniques
Early in the series, the ante situm procedure was used in patients in
whom tumours invaded the retrohepatic IVC. Following division
of the suprahepatic cava, the liver can be rotated anteriorly to afford
good access to the dorsal area of the liver close to the hepatocaval
confluence. There is little difference between this technique and
that of in situ hypothermic perfusion. The liver is first mobilized as
for TVE. A venovenous bypass is systematically installed from the
portal and femoral veins to the left internal jugular vein and deleted
dual cannulation of the portal vein is performed above the portal
triad clamp with a Silastic® (silicone elastomer) catheter (internal
diameter: 2.5 mm; external diameter: 4.5 mm). In situ hypother-
mic perfusion of the liver is then carried out with 2 l of University
of Wisconsin solution (UW), chilled to 4 °C. A cavotomy is per-
formed immediately above the inferior caval clamp to drain the
cold perfusate. When liver resection and vascular reconstruction
are completed, the liver is flushed with albumin to wash out the UW
solution via the portal vein. The portal catheter for perfusion is
removed and the portotomy and cavotomy are closed. Circulation
can then be restored as for TVE. The venovenous bypass is removed
as a last step, after haemodynamic stability is restored.
The unit operates an intensive policy of postoperative surveil-
lance and all patients received adjuvant chemotherapy unless they
had undergone chemotherapy adjuvant to bowel resection within
12 months of the primary hepatic resection.
Data were reviewed for all patients. These data included infor-
mation on the mode of presentation, operative and oncological
outcomes, the technique of vascular occlusion required for opera-
tion and the type of vena cava reconstruction performed. Hospital
mortality was defined as death within 30 days of surgery or during
the postoperative hospital stay. Postoperative complications were
documented according to the International Dindo–Clavien Clas-
sification.37 Positive margins were defined as evidence of tumour
at within 1 mm of the inked margin. Brisbane terminology was
used to define different hepatic resections and the diagnosis was
confirmed pathologically in all patients.38,39
Statistical analysis was carried out using spss for Windows
Version 17.0 (SPSS, Inc., Chicago, IL, USA). Categorical variables
were compared using the chi-squared test or Fisher’s exact test,
where appropriate. Longterm survival was calculated using the
Kaplan–Meier method.
Results
From February 1995 to September 2010, 2146 patients underwent
liver resection for tumour in the unit. Of these, 35 (1.6%) patients
Figure 3 Gore-Tex® graft for inferior vena cava (IVC) reconstruction
with use of IVC patch to reconstruct left hepatic vein
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underwent hepatectomy with IVC resection. Their median age
was 57 years (range: 32–84 years). Eighteen of the patients were
male. Resections were carried out for colorectal liver metastasis
(CRLM) (n = 21), HCC (n = 6), CC (n = 3) and other conditions
(n = 5).
Surgical procedures
Major hepatectomy (of at least three segments) was carried out in
30 patients and the caudate lobe was resected in 17 patients
(Table 1). The liver resections carried out included 32 first, two
second and one third hepatectomy. Resections were carried out
with total vascular occlusion in 34 patients and without in one. In
situ hypothermic perfusion was performed in 13 patients, ante
situm in three patients and ex vivo in six patients. The median
operative time was 255 min (range: 90–660 min) and transfusion
was necessary in 19 patients (median: 5 units).
Histopathological data of IVC involvement
Negative microscopic resection margins (R0) were achieved in 18
patients. Histological data showed the IVC to be involved by
tumour in 15 patients, not involved in 15 and of unknown status
in five patients. The median largest tumour circumference was
120 mm (range: 15–230 mm).
IVC reconstruction
The IVC underwent segmental resection and reconstruction with
synthetic grafts in 12 patients (Table 1). Dacron® and Gore-Tex®
were used in three and nine patients, respectively. Direct repair of
the IVC with or without a bovine pericardial patch was carried out
in 23 patients. All vascular reconstructions were patent at last
follow-up. There was no difference in overall survival between
patients who underwent direct repair of the IVC and patients in
whom graft replacement was necessary (P > 0.05).
In-hospital mortality
Four early deaths from multiple organ failure occurred. The
median postoperative hospital stay was 12 days (range: 6–45 days).
The patients who died included a 42-year-old woman who under-
went hepatectomy with ex vivo resection and re-implantation of
segment II and part of segment III with IVC reconstruction, but
developed multi-organ failure on the second postoperative day,
requiring ventilation and haemodialysis. A laparotomy was per-
formed for suspected abdominal sepsis the following day, but,
despite intensive support, the patient died on postoperative day
15. The second death occurred after right trisectionectomy with
IVC reconstruction in a 68-year-old man who had received inten-
sive preoperative chemotherapy. The patient died of unexplained
sepsis and multiple organ failure. The third patient developed
hepatic failure against a background of portal vein thrombosis
and eventually died from multiple organ failure on day 15. The
fourth patient died in the intensive care unit of multiple organ
failure on day 32.
Morbidity
Postoperative complications occurred in 14 patients, three of
whom required re-operation. Complications included acute renal
failure in three patients, hepatic encephalopathy in three, sepsis in
four, haemorrhage in two, superficial wound dehiscence in one,
wound infection in one and bile leak in one patient (one patient
developed acute renal failure with hepatic encephalopathy). The
three patients who needed re-laparotomy did so for haemorrhage
in two cases and unexplained sepsis in one. Two of the patients
who underwent re-laparotomy died. Table 2 shows the postopera-
tive complication rate according to the International Dindo–
Clavien Classification.
Survival analysis
Median overall survival was 29 months (95% confidence interval
[CI] 2.7–55.2 months). Overall actuarial 5-year survival was
37.7%. The Kaplan–Meier survival curve for all patients undergo-
ing hepatectomy with IVC reconstruction is shown in Fig. 4. The
actuarial 1-, 2- and 5-year survival rates were 75.9%, 58.7% and
19.6% for patients with CRLM. A subgroup analysis of patients
with colorectal metastases showed a median survival of 28 months
(95% CI 20.2–35.8 months). One-year survival rates in HCC and
CC patients were 83.3% and 33.3%, respectively. The Kaplan–
Meier survival curve for patients with CRLM is shown in Fig. 5.
Survival after an R0 resection was significantly better (P = 0.009)
(Fig. 6).
Discussion
The present study reviewed outcomes in 35 patients who under-
went partial hepatectomy with IVC reconstruction and who rep-
resent the largest patient series to be reported in the literature to
date. Tumours in the central and posterior segments of the liver
and occasionally those originating in the kidney, adrenal gland or
retroperitoneal soft tissue may extend to involve the IVC or
hepatic veins, making resection using standard techniques hazard-
ous.40,41 Consensus on best practice with regard to the selection of
patients, survival after these procedures, technique of IVC recon-
struction and type of artificial graft for IVC replacement remains
unachieved.
It is often difficult to define precisely the extent and nature of
contact between the tumour and IVC. Although most institutions
use a combination of CT and MRI prior to hepatic resection,
neither technique has proven to be accurate in diagnosing caval
involvement.42–45 Even when IVC invasion is strongly suggested by
conventional radiological studies, the surgeon should endeavour
to peel the tumour from the IVC as this is possible more often
than not. In our experience, outcomes are superior if the IVC is
not actually invaded.32
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When involvement of the IVC is below the level of the hepatic
veins and there is sufficient room to place a vascular clamp
above the tumour but below the hepatic veins, liver blood flow
can be maintained during resection and reconstruction of the
IVC. It is our preference to divide the liver parenchyma first
and to subsequently place the clamps on the IVC. However,
an alternative approach described by Madariaga et al. involves
replacing the IVC prior to dividing the liver parenchyma, but
this has not gained popular acceptance.46 Either approach
minimizes the time required for portal inflow occlusion as
normal livers can tolerate 60–90 min of warm ischaemia;
however, it would seem prudent to minimize ischaemic time
where possible.47,48
In selected patients with tumours that invade the right side of
the cava, the hanging manoeuvre can be applied so that the liver
parenchyma and IVC are transected and the cava then repaired. In
general, as much as possible of the liver is mobilized off the vena
cava prior to the transection of the hepatic parenchyma. However,
occasionally a large, bulky tumour makes the mobilization of the
liver off the vena cava difficult or even hazardous. In such cases, a
liver parenchymal transection using an anterior approach can be
performed first to expose the IVC without excessive rotation or
traction of the liver.
Although in situ hypothermic perfusion and the ante situm
technique are applicable in hepatic tumours involving the hepa-
tocaval confluence or the retrohepatic vena cava, the ex vivo bench
dissection was used in six patients in the present series. It is our
opinion that an ex vivo approach is only applicable in patients who
have extreme IVC, hepatocaval confluence and portal triad
involvement and more conservative approaches can be used in all
other contexts.
Different types of IVC repair can be applied, depending on the
extent of IVC infiltration by the tumour. Partial invasion of the
IVC wall is repaired by direct suture if the wall is infiltrated for a
short segment of <2 cm. A patch of autologous saphenous vein,
fascial peritoneum or heterologous material can be used in the
presence of extended infiltration of the wall (>2 cm) to prevent
lumen stenosis; however, we consider bovine pericardium to be
more convenient. Finally, total replacement of the IVC with a
vascular prosthesis is indicated if at least one half of the circum-
ference of the IVC appears infiltrated, in the presence of longitu-
dinal infiltration or, rarely, in the presence of an intracaval
thrombus.
There are a variety of options for replacing the IVC when
primary repair is not possible. Although replacement of the
resected IVC with an autogenous vein graft carries advantages
with regard to the risk for infection or thrombosis, this option
may not be technically feasible, particularly if a relatively long
segment of the IVC is to be replaced, and here synthetic grafts are
preferable. Dacron® has been used in the past, but has been asso-
Table 2 International Dindo–Clavien Classification of surgical
complications37 in the present series
Grade n
1 1 (wound infection)
2 1 (superficial wound dehiscence)
3a 1 (bile leak)
3b 3 (haemorrhage, 2; sepsis, 1)
4a 6 (renal failure, 3; hepatic encephalopathy, 3)
4b 4 (multiple organ dysfunction)
5 4 (death)
Figure 4 Kaplan–Meier survival curve for all patients undergoing inferior vena cava resection with hepatectomy
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ciated with relatively high thrombosis and stenosis rates and
therefore we prefer to use reinforced PTFE grafts for replacing the
IVC as they seem to resist compression by the abdominal vis-
cera.32,45,47,48 Although the risk for graft thrombosis may be
reduced by postoperative anticoagulation, the value of anticoagu-
lation remains questionable and the required duration of therapy
is hard to determine.49 We have used anticoagulants and formed
arteriovenous fistulas in the past, but no longer feel these manoeu-
vres are necessary as the IVC flows are high.
Despite the availability of innovative surgical techniques that
render extensive hepatic resection and concomitant IVC replace-
ment feasible, the surgical death and complication rates associated
with this type of surgery remain considerable. In preoperative
assessment an exercise electrocardiogram or a stress echocardio-
gram is performed in all patients undergoing workup for major
hepatic surgery and CPX is used increasingly. The benefits to these
patients of including in the surgical team an anaesthetist experi-
enced in low venous pressure techniques as well as highcentral
Figure 5 Actuarial survival curves in patients with colorectal liver metastasis
Figure 6 Kaplan–Meier survival curves for patients undergoing R0 and R1 resections. P = 0.009
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venous pressure transplant anaesthesia for venovenous bypass
cannot be underestimated.
Although disease in this group of patients represents an
advanced stage of metastasis and overall survival is still unsatis-
factory, this approach – using extensive surgery – is worth
attempting because surgical resection currently provides the only
hope for cure in this patient group and the technique has been
established as relatively safe. At present, metastasis that impinges
on the hepatic vasculature must be considered from a technical
perspective insofar as it relates to resectability, but it has not
been reliably identified as an independent adverse prognostic
factor.50,51
In conclusion, the major findings of this study show that in
selected patients with hepatobiliary malignancy involving the IVC,
the use of specialized vascular techniques can offer potentially
prolonged survival. These procedures should be performed in
high-volume centres experienced in the use of advanced vascular
isolation procedures.
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